130 related articles for article (PubMed ID: 19002424)
1. Permanent silencing of NKG2A expression for cell-based therapeutics.
Figueiredo C; Seltsam A; Blasczyk R
J Mol Med (Berl); 2009 Feb; 87(2):199-210. PubMed ID: 19002424
[TBL] [Abstract][Full Text] [Related]
2. Multimeric immunotherapeutic complexes activating natural killer cells towards HIV-1 cure.
Schober R; Brandus B; Laeremans T; Iserentant G; Rolin C; Dessilly G; Zimmer J; Moutschen M; Aerts JL; Dervillez X; Seguin-Devaux C
J Transl Med; 2023 Nov; 21(1):791. PubMed ID: 37936122
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus peptides derived from latent cycle proteins alter NKG2A + NK cell effector function.
Mbiribindi B; Pena JK; Arvedson MP; Moreno Romero C; McCarthy SR; Hatton OL; Esquivel CO; Martinez OM; Krams SM
Sci Rep; 2020 Nov; 10(1):19973. PubMed ID: 33203899
[TBL] [Abstract][Full Text] [Related]
4. Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors.
Suerth JD; Morgan MA; Kloess S; Heckl D; Neudörfl C; Falk CS; Koehl U; Schambach A
J Mol Med (Berl); 2016 Jan; 94(1):83-93. PubMed ID: 26300042
[TBL] [Abstract][Full Text] [Related]
5. Identification of NKG2A and NKp80 as specific natural killer cell markers in rhesus and pigtailed monkeys.
Mavilio D; Benjamin J; Kim D; Lombardo G; Daucher M; Kinter A; Nies-Kraske E; Marcenaro E; Moretta A; Fauci AS
Blood; 2005 Sep; 106(5):1718-25. PubMed ID: 15899917
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia.
Orleans-Lindsay JK; Barber LD; Prentice HG; Lowdell MW
Clin Exp Immunol; 2001 Dec; 126(3):403-11. PubMed ID: 11737054
[TBL] [Abstract][Full Text] [Related]
7. The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells.
Kaulfuss M; Mietz J; Fabri A; Vom Berg J; Münz C; Chijioke O
Sci Rep; 2023 Jun; 13(1):10555. PubMed ID: 37386090
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of NK cell function by flowcytometric measurement and impedance based assay using real-time cell electronic sensing system.
Park KH; Park H; Kim M; Kim Y; Han K; Oh EJ
Biomed Res Int; 2013; 2013():210726. PubMed ID: 24236291
[TBL] [Abstract][Full Text] [Related]
9. Limocitrin increases cytotoxicity of KHYG-1 cells against K562 cells by modulating MAPK pathway.
Hsieh MJ; Lin JT; Chuang YC; Lin CC; Lo YS; Ho HY; Chen MK
Environ Toxicol; 2023 Dec; 38(12):2939-2951. PubMed ID: 37584500
[TBL] [Abstract][Full Text] [Related]
10. NKG2A discriminates natural killer cells with a suppressed phenotype in pediatric acute leukemia.
Ulvmoen A; Greiff V; Bechensteen AG; Inngjerdingen M
J Leukoc Biol; 2024 Jan; 115(2):334-343. PubMed ID: 37738462
[TBL] [Abstract][Full Text] [Related]
11. Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A.
Ayass MA; Tripathi T; Griko N; Okyay T; Ramankutty Nair R; Zhang J; Zhu K; Melendez K; Pashkov V; Abi-Mosleh L
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473398
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells.
Mohammadian Gol T; Kim M; Sinn R; Ureña-Bailén G; Stegmeyer S; Gratz PG; Zahedipour F; Roig-Merino A; Antony JS; Mezger M
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003255
[TBL] [Abstract][Full Text] [Related]
13. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Apr; 140():109777. PubMed ID: 32344314
[TBL] [Abstract][Full Text] [Related]
14. Cutting edge: KIR antisense transcripts are processed into a 28-base PIWI-like RNA in human NK cells.
Cichocki F; Lenvik T; Sharma N; Yun G; Anderson SK; Miller JS
J Immunol; 2010 Aug; 185(4):2009-12. PubMed ID: 20631304
[TBL] [Abstract][Full Text] [Related]
15. Exploring NK cell receptor dynamics in paediatric leukaemias: implications for immunotherapy and prognosis.
Tu C; Buckle I; Leal Rojas I; Rossi GR; Sester DP; Moore AS; Radford K; Guillerey C; Souza-Fonseca-Guimaraes F
Clin Transl Immunology; 2024; 13(3):e1501. PubMed ID: 38525380
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer.
Fisher JG; Doyle ADP; Graham LV; Khakoo SI; Blunt MD
Vaccines (Basel); 2022 Nov; 10(12):. PubMed ID: 36560403
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific targeting of a cell line with natural killer cell activity by asialoglycoprotein receptor gene transfer.
Schirrmann T; Pecher G
Cancer Immunol Immunother; 2001 Dec; 50(10):549-56. PubMed ID: 11776377
[TBL] [Abstract][Full Text] [Related]
18. Gender as a factor affecting NK cell activity in patients successfully treated for chronic hepatitis C with direct-acting antivirals.
Zientarska A; Mikuła-Pietrasik J; Kaczmarek M; Witkowska A; Rozpłochowski B; Kowala-Piaskowska A; Książek K; Żeromski J; Mozer-Lisewska I
Cent Eur J Immunol; 2021; 46(4):481-491. PubMed ID: 35125947
[TBL] [Abstract][Full Text] [Related]
19. Deep phenotyping characterization of human unconventional CD8
Orta-Resendiz A; Petitdemange C; Schmutz S; Jacquelin B; Novault S; Huot N; Müller-Trutwin M
STAR Protoc; 2023 Dec; 4(4):102734. PubMed ID: 38032799
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometry-based functional selection of RNA interference triggers for efficient epi-allelic analysis of therapeutic targets.
Micklem DR; Blø M; Bergström P; Hodneland E; Tiron C; Høiby T; Gjerdrum C; Hammarsten O; Lorens JB
BMC Biotechnol; 2014 Jun; 14():57. PubMed ID: 24952598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
